3 results
Approved WMORecruiting
Primary: To assess the efficacy of treatment with 300 mg or 600 mg of intravenous (IV) zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily on time to clinical response. Secondary: reduction in viral load from nasopharyngeal swabs…
Approved WMOCompleted
In the Phase 2 clinical study, the efficacy of the vaccine in non-responders and the safety of the vaccine will be studied.
Approved WMOCompleted
To assess piperacillin concentrations during continuous dosing of P/T in critically ill patients; to determine PK variables, e.g. creatinine clearance, leading to a predictive mathematical model enabling TDM and ideally establishing better a priori…